Vera Therapeutics (VERA) has drawn fresh attention after a recent share price move, with the stock up around 10% over the past day and showing similar gains over the past week.

Zooming out, the recent 10.23% 7 day share price return sits against a 7.14% 30 day gain but a 7.36% year to date share price decline. The 1 year total shareholder return is 100.8% and the 3 year total shareholder return is more than 6x, suggesting momentum has been rebuilding after a weaker patch.

If you are looking beyond Vera Therapeutics for other ideas in healthcare, this is a good time to scan for potential opportunities in 31 healthcare AI stocks

With Vera Therapeutics trading at US$45.04 against an analyst price target of US$79.00 and a very large intrinsic discount flagged, the key question is whether this reflects a genuine opportunity or a market that is already pricing in future growth.

Price to Book of 5.3x: Is It Justified?

Vera Therapeutics is trading on a P/B of 5.3x, which sits below the peer average but above the broader US biotech industry. This means the market is attaching a premium to its balance sheet while still pricing it below closer peers.

P/B compares the company’s market value to its net assets. This can be useful for development stage biotechs that are not yet generating meaningful revenue or profits. In this case, the current P/B of 5.3x suggests investors are willing to pay several times the accounting value of Vera Therapeutics' assets, reflecting expectations for future clinical and commercial progress rather than current earnings.

The US biotech industry average P/B is 2.3x, so Vera Therapeutics trades at more than double the broader group. However, compared with a peer average P/B of 6.5x, the shares are at a discount. This points to the market assigning a lower valuation than some closer comparables, even though the company screens as good value on this metric within that peer set.

Result: Price-to-book of 5.3x (ABOUT RIGHT)

However, you also need to weigh clinical and regulatory uncertainty around atacicept and other pipeline assets, along with ongoing losses of US$299.615 million that require continued funding.

Another View: What Does The DCF Say?

The price to book of 5.3x paints Vera Therapeutics as roughly in line with peers, but the SWS DCF model points in a very different direction, with an estimated future cash flow value of US$436.34 per share versus the current US$45.04. This suggests the stock screens as heavily undervalued on this approach.

When one method hints at a fair balance sheet premium and another flags a very large intrinsic discount, the real question is which set of assumptions you trust more for a clinical stage biotech still losing US$299.615 million a year.

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Vera Therapeutics for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 58 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

If this mix of risks and rewards feels finely balanced, it is worth checking the underlying data now and deciding where you stand. To see both sides in one place, take a closer look at the 2 key rewards and 2 important warning signs

Looking for more investment ideas?

If Vera Therapeutics has caught your interest, now is a smart moment to widen your watchlist and compare it with other focused opportunities across the market.

• Target potential bargains by scanning companies that appear attractively priced relative to quality using the 58 high quality undervalued stocks.
• Prioritize resilience by filtering for companies with strong financial footing through the solid balance sheet and fundamentals stocks screener (41 results).
• Spot under the radar opportunities with solid fundamentals before they gain wider attention using the screener containing 23 high quality undiscovered gems.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.